Walleye Capital’s Novavax NVAX Stock Holding History

Walleye Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$309K	Sell	37,920 -51,639	-58%	-$468K	﹤0.01%	3045
2025 Q4	$602K	Buy	89,559 +76,525	+587%	+$577K	﹤0.01%	2837
2025 Q3	$113K	Sell	13,034 -31,159	-71%	-$243K	﹤0.01%	3655
2025 Q2	$278K	Buy	44,193 +25,790	+140%	+$171K	﹤0.01%	3103
2025 Q1	$118K	Sell	18,403 -12,307	-40%	-$102K	﹤0.01%	3549
2024 Q4	$247K	Sell	30,710 -29,259	-49%	-$282K	﹤0.01%	3594
2024 Q3	$757K	Sell	59,969 -333,948	-85%	-$4.31M	﹤0.01%	2926
2024 Q2	$4.99M	Buy	393,917 +392,035	+20,831%	+$3.94M	0.01%	1291
2024 Q1	$9K	Buy	+1,882	New	+$8.73K	﹤0.01%	5081
2023 Q3	–	Sell	-56,283	Closed	-$418K	–	5185
2023 Q2	$418K	Buy	+56,283	New	+$443K	﹤0.01%	2562
2023 Q1	–	Sell	-109,536	Closed	-$1.01M	–	4236
2022 Q4	$1.13M	Buy	109,536 +34,335	+46%	+$606K	0.02%	924
2022 Q3	$1.37M	Buy	+75,201	New	+$3.26M	0.03%	762
2022 Q2	–	Sell	-10,273	Closed	-$757K	–	2612
2022 Q1	$757K	Buy	+10,273	New	+$916K	0.02%	773

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's NVAX Position: Q1 2026 in Review

Walleye Capital reduced its Novavax (NVAX) stake by 58% in Q1 2026, selling an estimated $468K and leaving 37,920 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

Walleye Capital first reported a position in NVAX in Q1 2022 and has held it in 13 quarters since. The position peaked at $4.99M in Q2 2024. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

Walleye Capital held 37,920 shares of Novavax worth $309K as of Q1 2026.
Walleye Capital sold 51,639 Novavax shares in Q1 2026, an estimated $468K.
Novavax made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3045 holding.
Walleye Capital first reported a position in Novavax in Q1 2022 and has held it in 13 quarters since.
Walleye Capital's Novavax position peaked at $4.99M in Q2 2024.
257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.